Skip Nav Destination
Response of ETV6-FLT3–positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3
Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study
Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis
Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α
Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia
Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia
Issue Archive
August 25 2011
In this Issue
Table of Contents
Inside Blood
Perspectives
Review Article
Clinical Trials and Observations
Response of ETV6-FLT3–positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3
Brief Report
Christoph Walz,Philipp Erben,Michael Ritter,Adrian Bloor,Georgia Metzgeroth,Nick Telford,Claudia Haferlach,Torsten Haferlach,Stefan Gesk,Joannah Score,Wolf-Karsten Hofmann,Andreas Hochhaus,Nicholas C. P. Cross,Andreas Reiter
Hematopoiesis and Stem Cells
Immunobiology
Escape from highly effective public CD8+ T-cell clonotypes by HIV
Maria Candela Iglesias,Jorge R. Almeida,Solène Fastenackels,David J. van Bockel,Masao Hashimoto,Vanessa Venturi,Emma Gostick,Alejandra Urrutia,Linda Wooldridge,Mathew Clement,Stéphanie Gras,Pascal G. Wilmann,Brigitte Autran,Arnaud Moris,Jamie Rossjohn,Miles P. Davenport,Masafumi Takiguchi,Christian Brander,Daniel C. Douek,Anthony D. Kelleher,David A. Price,Victor Appay
Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways
Magdalena A. Berkowska,Gertjan J. A. Driessen,Vasilis Bikos,Christina Grosserichter-Wagener,Kostas Stamatopoulos,Andrea Cerutti,Bing He,Katharina Biermann,Johan F. Lange,Mirjam van der Burg,Jacques J. M. van Dongen,Menno C. van Zelm
Lymphoid Neoplasia
Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia
Clinical Trials & Observations
Sameer A. Parikh,Michael J. Keating,Susan O'Brien,Xuemei Wang,Alessandra Ferrajoli,Stefan Faderl,Jan Burger,Charles Koller,Zeev Estrov,Xavier Badoux,Susan Lerner,William G. Wierda
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study
Clinical Trials & Observations
Martin Schrappe,Maria Grazia Valsecchi,Claus R. Bartram,André Schrauder,Renate Panzer-Grümayer,Anja Möricke,Rosanna Parasole,Martin Zimmermann,Michael Dworzak,Barbara Buldini,Alfred Reiter,Giuseppe Basso,Thomas Klingebiel,Chiara Messina,Richard Ratei,Giovanni Cazzaniga,Rolf Koehler,Franco Locatelli,Beat W. Schäfer,Maurizio Aricò,Karl Welte,Jacques J.M. van Dongen,Helmut Gadner,Andrea Biondi,Valentino Conter
Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia
Clinical Trials & Observations
Xavier C. Badoux,Michael J. Keating,Xuemei Wang,Susan M. O'Brien,Alessandra Ferrajoli,Stefan Faderl,Jan Burger,Charles Koller,Susan Lerner,Hagop Kantarjian,William G. Wierda
Differential and tumor-specific expression of CD160 in B-cell malignancies
Timothy W. Farren,Jerome Giustiniani,Feng-Ting Liu,Dimitris A. Tsitsikas,Marion G. Macey,James D. Cavenagh,Heather E. Oakervee,David Taussig,Adrian C. Newland,Maria Calaminici,Armand Bensussan,Michael Jenner,John G. Gribben,Samir G. Agrawal
Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia
Eugene Park,Eun Ji Gang,Yao-Te Hsieh,Paul Schaefer,Sanna Chae,Lars Klemm,Sandra Huantes,Mignon Loh,Edward M. Conway,Eun-Suk Kang,Hong Hoe Koo,Wolf-Karsten Hofmann,Nora Heisterkamp,Louis Pelus,Ganesan Keerthivasan,John Crispino,Michael Kahn,Markus Müschen,Yong-Mi Kim
Myeloid Neoplasia
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis
Clinical Trials & Observations
Paola Guglielmelli,Giovanni Barosi,Alessandro Rambaldi,Roberto Marchioli,Arianna Masciulli,Lorenzo Tozzi,Flavia Biamonte,Niccolò Bartalucci,Elisabetta Gattoni,Maria Letizia Lupo,Guido Finazzi,Alessandro Pancrazzi,Elisabetta Antonioli,Maria Chiara Susini,Lisa Pieri,Elisa Malevolti,Emilio Usala,Ubaldo Occhini,Alberto Grossi,Silvia Caglio,Simona Paratore,Alberto Bosi,Tiziano Barbui,Alessandro M. Vannucchi,on behalf of the AIRC-Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators
Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice
Simon F. Lacey,Corinna La Rosa,Teodora Kaltcheva,Tumul Srivastava,Aprille Seidel,Wendi Zhou,Ravindra Rawal,Katharine Hagen,Aparna Krishnan,Jeff Longmate,Helen A. Andersson,Lisa St. John,Ravi Bhatia,Vinod Pullarkat,Stephen J. Forman,Laurence J. N. Cooper,Jeffrey Molldrem,Don J. Diamond
Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α
Brief Report
Caroline Hasselbalch Riley,Morten Krogh Jensen,Marie Klinge Brimnes,Hans Carl Hasselbalch,Ole Weis Bjerrum,Per thor Straten,Inge Marie Svane
Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia
Brief Report
Kate A. Alford,Katarina Reinhardt,Catherine Garnett,Alice Norton,Katarina Böhmer,Christine von Neuhoff,Alexandra Kolenova,Emanuele Marchi,Jan-Henning Klusmann,Irene Roberts,Henrik Hasle,Dirk Reinhardt,Paresh Vyas,on behalf of the International Myeloid Leukemia–Down Syndrome Study Group
Phagocytes, Granulocytes, and Myelopoiesis
A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells
Samantha Solito,Erika Falisi,Claudia Marcela Diaz-Montero,Andrea Doni,Laura Pinton,Antonio Rosato,Samuela Francescato,Giuseppe Basso,Paola Zanovello,Georgiana Onicescu,Elizabeth Garrett-Mayer,Alberto J. Montero,Vincenzo Bronte,Susanna Mandruzzato
Platelets and Thrombopoiesis
Red Cells, Iron, and Erythropoiesis
Thrombosis and Hemostasis
The vitronectin-binding function of PAI-1 exacerbates lung fibrosis in mice
Anthony J. Courey,Jeffrey C. Horowitz,Kevin K. Kim,Timothy J. Koh,Margaret L. Novak,Natalya Subbotina,Mark Warnock,Bing Xue,Andrew K. Cunningham,Yujing Lin,Monica P. Goldklang,Richard H. Simon,Daniel A. Lawrence,Thomas H. Sisson
Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells
Nadine Prinz,Natascha Clemens,Dennis Strand,Inge Pütz,Mareike Lorenz,Andreas Daiber,Pamela Stein,Adriana Degreif,Markus Radsak,Hansjörg Schild,Stefan Bauer,Philipp von Landenberg,Karl J. Lackner
Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide
Henrik Østergaard,Jais R. Bjelke,Lene Hansen,Lars Christian Petersen,Anette A. Pedersen,Torben Elm,Flemming Møller,Mette B. Hermit,Pernille K. Holm,Thomas N. Krogh,Jørn M. Petersen,Mirella Ezban,Brit B. Sørensen,Mette D. Andersen,Henrik Agersø,Haleh Ahmadian,Kristoffer W. Balling,Marie Louise S. Christiansen,Karin Knobe,Timothy C. Nichols,Søren E. Bjørn,Mikael Tranholm
Transplantation
Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia
Clinical Trials & Observations
Judith C. Marsh,Vikas Gupta,ZiYi Lim,Aloysius Y. Ho,Robin M. Ireland,Janet Hayden,Victoria Potter,Mickey B. Koh,M. Serajul Islam,Nigel Russell,David I. Marks,Ghulam J. Mufti,Antonio Pagliuca
Vascular Biology
Other Departments
-
Cover Image
Cover Image
![issue cover]()
Immunofluorescence image of endothelial cell (EC, green) colony formed by differentiation of Flk-1+ mesodermal precursor cells derived from mouse embryonic stem cells. Supplemental angiopoietin-1 promotes both EC proliferation (phospho-histone H3, pink) and EC colony formation from Flk-1+ mesodermal precursor cells. Nuclei are stained with Hoechst (blue). Image by Hyung Joon Joo. See the article by Joo et al on page 2094.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals
